바로가기메뉴

본문 바로가기 주메뉴 바로가기

ACOMS+ 및 학술지 리포지터리 설명회

  • 한국과학기술정보연구원(KISTI) 서울분원 대회의실(별관 3층)
  • 2024년 07월 03일(수) 13:30
사전등록 바로가기
 

logo

메뉴
search

ISSN : 0376-4672

논문 상세

이전 다음
논문 투고

52권 4호

Bisphosphonate-related osteonecrosis of the jaw(BRONJ)에대한 biochemical bone markers와악골괴사와연관된nonbisphosphonate drugs

Biochemical bone markers of bisphosphonate-related osteonecrosis of the jaw (BRONJ) and nonbisphosphonate drugs in osteonecrosis of the jaw

이덕원 (경희대학교 일반대학원 치의학과 구강악안면외과학)
이현우 (경희대학교 치의학전문대학원 구강악안면외과학교실)
권용대 (경희대학교)
대한치과의사협회지 / The Journal of the Korean Dental Association, (P)0376-4672; (E)2713-7961
2014, v.52 no.4, pp.203-217
https://doi.org/10.22974/jkda.2014.52.4.002
이덕원, 이현우, & 권용대. (2014). Bisphosphonate-related osteonecrosis of the jaw(BRONJ)에대한 biochemical bone markers와악골괴사와연관된nonbisphosphonate drugs. 대한치과의사협회지, 52(4), 203-217, https://doi.org/10.22974/jkda.2014.52.4.002

Abstract

Bisphosphonate는 골다공증, 골감소증, 전이성골질환, Paget’s disease 등과 같은 대사성 골 질환의 치료와 다발성 골수종과 종양의 전이와 관련된 골격적 합병증의 조절을 위해 십 년 이상 사용되어온 골흡수 억제재이다. Bisphosphonate는 phosphoether결합(인-탄소-인의 사슬)을 가지는 화학물질로 활동성 파골세포사이 및 골 흡수면에 선택적으로 침착되어 파골세포의기능을 저하시켜서 골흡수를 억제한다. 이에 따라 골모세포의 활성 정도가 감소되어 전반적인 골의 교체율을 낮추는 효과를 보인다. 또한 악성 질환에서 고칼슘혈증치료에 석회화를 방해하는 작용을 하며 부가적으로 관절염 치료에 관절 내의 염증반응을 감소시키는약물작용을 한다고 알려져 있다1). 이러한 효과적인 골흡수 억제재임에고 불구하고 bisphosphonate를 장기간 사용한 경우 악골에서 골 노출, 턱뼈의 괴사라는부작용이 발생하는 경우가 보고되고 있으며 이를bisphosphonate-related osteonecrosis ofthe jaw(BRONJ)로 명명하고 있다.

keywords
Bisphosphonate-related osteonecrosis of the jaw(BRONJ), Biochemical bone marker, nonbisphosphonate drugs

참고문헌

1.

1. Saad, F. and A. Lipton, Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol, 2007. 34(6Suppl 4): p. S17-23.

2.

2. Marx, R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws:a growing epidemic. J Oral Maxillofac Surg, 2003. 61(9): p. 1115-7.

3.

3. Lazarovici, T.S., et al., Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. J Oral Maxillofac Surg, 2010. 68(9): p. 2241-7.

4.

4. Khosla, S., et al., Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res, 2007. 22(10): p. 1479-91.

5.

5. Ruggiero, S.L., et al., American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw -2009 update. Aust Endod J, 2009. 35(3): p. 119-30.

6.

6. Williamson, R.A., Surgical management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral Maxillofac Surg, 2010. 39(3): p. 251-5.

7.

7. Carlson, E.R. and J.D. Basile, The role of surgical resection in the management of bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(5 Suppl): p. 85-95.

8.

8. Vasikaran, S., et al., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int, 2011. 22(2):p. 391-420.

9.

9. Rosen, H.N., et al., Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int, 2000. 66(2): p. 100-3.

10.

10. Marx, R.E., J.E. Cillo, Jr., and J.J. Ulloa, Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg, 2007. 65(12): p. 2397-410.

11.

11. Schwartz, H.C., Serum CTX testing. J Oral Maxillofac Surg, 2008. 66(6): p. 1319-20; author reply 1320.

12.

12. Kwon, Y.D., et al., Correlation between serum Cterminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(12): p. 2644-8.

13.

13. Bagan, J.V., et al., Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncol, 2008. 44(11): p. 1088-9.

14.

14. Kunchur, R., et al., Clinical investigation of Cterminal cross-linking telopeptide test in prevention and management of bisphosphonateassociated osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(6): p. 1167-73.

15.

15. Ardine, M., et al., Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw? Ann Oncol, 2006. 17(8): p. 1336-7.

16.

16. Lehrer, S., et al., Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2008. 106(3): p. 389-91.

17.

17. Kim, J.W., et al., Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone, 2013. 57(1): p. 201-5.

18.

18. Martinez, J., et al., Bone turnover markers in Spanish postmenopausal women: the Camargo cohort study. Clin Chim Acta, 2009. 409(1-2): p. 70-4.

19.

19. Trento, L.K., et al., Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. J Obstet Gynaecol Res, 2009. 35(1): p. 152-9.

20.

20. Lee, J.J., et al., Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study. Head Neck, 2013. 35(12): p. 1787-95.

21.

21. Bowers, G.N., Jr. and R.B. McComb, Measurement of total alkaline phosphatase activity in human serum. Clin Chem, 1975. 21(13): p. 1988-95.

22.

22. Raisz, L., et al., Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int, 2000. 11(7): p. 615-20.

23.

23. Looker, A.C., et al., Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int, 2000. 11(6): p. 467-80.

24.

24. Baim, S. and P.D. Miller, Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res, 2009. 24(4): p. 561-74.

25.

25. Lehrer, S., et al., Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg, 2009. 67(1): p. 159-61.

26.

26. Kwon, Y.D., et al., Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Clin Oral Implants Res, 2011. 22(1): p. 100-5.

27.

27. in Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. 1997: Washington (DC).

28.

28. Holick, M.F., Vitamin D deficiency. N Engl J Med, 2007. 357(3): p. 266-81.

29.

29. Hwang, Y.C., et al., Optimal serum concentration of 25-hydroxyvitamin D for bone health in older Korean adults. Calcif Tissue Int, 2013. 92(1): p. 68-74.

30.

30. MacLaughlin, J. and M.F. Holick, Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest, 1985. 76(4): p. 1536-8.

31.

31. Hokugo, A., et al., Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res, 2010. 25(6): p. 1337-49.

32.

32. Kim, S.W., et al., Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis. Endocr J, 2005. 52(6): p. 667-74.

33.

33. Pazianas, M., Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst, 2011. 103(3): p. 232-40.

34.

34. Baron, R., S. Ferrari, and R.G. Russell, Denosumab and bisphosphonates: different mechanisms of action and effects. Bone, 2011. 48(4): p. 677-92.

35.

35. Troeltzsch, M., et al., Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc, 2012. 78: p. c85.

36.

36. Bekker, P.J., et al., A single-dose placebocontrolled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res, 2004. 19(7): p. 1059-66.

37.

37. Lumachi, F., et al., Cancer-induced hypercalcemia. Anticancer Res, 2009. 29(5): p. 1551-5.

38.

38. Sivolella, S., et al., Denosumab and antiangiogenetic drug-related osteonecrosis of the jaw: an uncommon but potentially severe disease. Anticancer Res, 2013. 33(5): p. 1793-7.

39.

39. Guarneri, V., et al., Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat, 2010. 122(1): p. 181-8.

40.

40. Lazarovici, T.S., et al., Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg, 2009. 67(4): p. 850-5.

41.

41. Hoff, A.O., et al., Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res, 2008. 23(6):p. 826-36.

42.

42. Harper, K.D., et al., Osteosarcoma and teriparatide? J Bone Miner Res, 2007. 22(2): p. 334.

43.

43. Kwon, Y.D., et al., Short-term teriparatide therapy as an adjunctive modality for bisphosphonaterelated osteonecrosis of the jaws. Osteoporos Int, 2012. 23(11): p. 2721-5.

44.

44. Narvaez, J., et al., Lack of response to teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw. Osteoporos Int, 2013. 24(2): p. 731-3.

45.

45. Adornato, M.C., I. Morcos, and J. Rozanski, The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc, 2007. 138(7): p. 971-7.

46.

46. Freiberger, J.J., Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg, 2009. 67(5Suppl): p. 96-106.

47.

47. Curtis, J.R., et al., Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporos Int, 2008. 19(11): p. 1613-20.

48.

48. Kwon, Y.D., et al., Oral bisphosphonate-related osteonecrosis of the jaws: favorable outcome after bisphosphonate holiday. Quintessence Int, 2009. 40(4): p. 277-8.

49.

49. Thumbigere-Math, V., et al., Bisphosphonaterelated osteonecrosis of the jaw: clinical features, risk factors, management, and treatment outcomes of 26 patients. J Oral Maxillofac Surg, 2009. 67(9): p. 1904-13.

logo

논문 투고
OA 정책